Company Overview

Samsrita Labs Limited (BSE: 539267, MSEI: SAMSRITA) has submitted its 30th Annual General Meeting notice and FY2025-26 financial results, revealing significant corporate restructuring and financial challenges.

Financial Performance

For FY2025-26, the company reported a substantial standalone net loss of ₹8.69 crore on minimal revenue of ₹1.81 lakh, compared to a loss of ₹25.95 lakh in the previous year. The consolidated net loss stood at ₹8.16 crore. The poor performance was primarily driven by major write-offs including ₹32.60 million in intangible assets, ₹25.93 million in related party advances, and ₹20.90 million in bad debts. Key financial ratios deteriorated significantly, with current ratio declining to 1.003 from 1.59 and return on equity at (0.69).

Capital Restructuring

The company proposes a substantial 50% capital reduction through a scheme that would reduce paid-up capital from ₹22.75 crore to ₹11.37 crore by canceling one share for every two held. This requires NCLT approval under Section 66 of the Companies Act, 2013. The rationale cited is that accumulated losses have substantially wiped off the value represented by share capital, necessitating realignment between capital and assets.

Equity Issuance and Ownership Changes

During the year, the company executed a preferential issue raising ₹7.94 crore through:

  • 33,91,000 shares issued for cash at ₹10 per share (₹3.39 crore)
  • 45,50,004 shares issued through share swap acquiring 28.62% stake in QROPS Advisory Services

This issuance significantly altered the ownership structure, reducing promoter K. Krishnam Raju's holding from 19.58% to 11.21% and introducing new significant shareholders.

AGM Agenda and Corporate Developments

The 30th AGM is scheduled for August 10, 2026, with key agenda items including:

  • Appointment of two new directors (Ravi Kanth Naga Pattabhi Chopperla and Satyanarayana Murthy Varanasi)
  • Alteration of MOA to enter pet animal healthcare business
  • Approval of ₹15 crore material related party transaction with QROPS Advisory
  • Adoption of financial statements and re-appointment of directors

Operational and Financial Position

The company's operations were sustained by unsecured, interest-free promoter loans totaling ₹16.62 million. Investments in associate companies (Krisani Bio Sciences and QROPS Advisory) were valued at ₹9.42 crore. The company holds cash equivalents of ₹1.63 crore but has negative reserves and surplus of ₹11.41 crore, indicating a weakened financial position.